State-of-the-art antibody technology and recent discoveries in neuroimmunolgy
About Braincure Biotech
Braincure Biotech is dedicated to pursuing the development and commercialization of novel treatment approaches in the fight against dementias, with a particular focus on Alzheimer’s Disease.
Our vision is to apply what we know about the effect of momentum stimulation on improved cognitive function to create a new and more effective treatment paradigm. For the millions of people living with, or in fear of, an Alzheimer’s diagnosis, our success could mean hope for the future and a lifetime preserved. Our goal is the development and commercialization of a medical device with the potential to arrest or significantly slow Alzheimer’s Disease progression.
Braincure Biotech is combining state-of-the-art antibody technology and recent discoveries in neuroimmunolgy and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically similar disorders. Braincure Biotech’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with the industry leaders in discovery and optimization of antibody therapeutics. Braincure Biotech is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and enabling studies within 24 months. Braincure Biotech has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.
Our goal is to discover and develop novel, disease modifying therapies for dementia and mechanistically similar disorders.
We design, discover and develop therapeutic and diagnostic products to prevent and modify diseases caused by misfolding proteins. Braincure Biotech’s two proprietary technology platforms create antibodies, small molecules and vaccines to address large markets across a broad spectrum neurodegenerative disorders.
Alzheimer’s disease (AD) is the largest indication addressed by our products but Braincure Biotech’s innovative, highly differentiated and disease-modifying therapies are capable of shifting the paradigm in the treatment of other neurodegenerative diseases such as Down syndrome, Parkinson’s disease, Tauopathies, Glaucoma and Huntington’s.
The most advanced of these is Braincreuzen, an anti-Abeta antibody that is licensed to Genentech entering phase III development.
Alzheimer’s disease affects 44 million people worldwide and by 2030 this number will rise to 76 million at a cost of care of $408 billion. Current therapies have proven to be effective only for a limited period of time and do not significantly delay disease progression. In contrast, Braincure Biotech’s therapies are designed to prevent, modify, delay or stop disease progression.